@article{Pennell:2014:10.1182/blood-2013-04-497842,
author = {Pennell, DJ and Porter, JB and Piga, A and Lai, Y and El-Beshlawy, A and Belhoul, KM and Elalfy, M and Yesilipek, A and Kilinc, Y and Lawniczek, T and Habr, D and Weisskopf, M and Zhang, Y and Aydinok, Y},
doi = {10.1182/blood-2013-04-497842},
journal = {Blood},
pages = {1447--1454},
title = {A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)},
url = {http://dx.doi.org/10.1182/blood-2013-04-497842},
volume = {123},
year = {2014}
}

Download

TY  - JOUR
AB  - Randomized comparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion dependent patients are lacking. CORDELIA was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneous deferoxamine (50-60 mg/kg per day for 5-7 days/week) for myocardial iron removal in 197 β-thalassemia major patients with myocardial siderosis (T2 6-20 milliseconds) and no signs of cardiac dysfunction (mean age, 19.8 years). Primary objective was to demonstrate noninferiority of deferasirox for myocardial iron removal, assessed by changes in myocardial T2 after 1 year using a per-protocol analysis. Geometric mean (Gmean) myocardial T2 improved with deferasirox from 11.2 milliseconds at baseline to 12.6 milliseconds at 1 year (Gmeans ratio, 1.12) and with deferoxamine (11.6 milliseconds to 12.3 milliseconds; Gmeans ratio, 1.07). The between-arm Gmeans ratio was 1.056 (95% confidence interval [CI], 0.998, 1.133). The lower 95% CI boundary was greater than the prespecified margin of 0.9, establishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of deferasirox). Left ventricular ejection fraction remained stable in both arms. Frequency of drug-related adverse events was comparable between deferasirox (35.4%) and deferoxamine (30.8%). CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial iron removal. This trial is registered at www.clinicaltrials.gov as #NCT00600938.
AU  - Pennell,DJ
AU  - Porter,JB
AU  - Piga,A
AU  - Lai,Y
AU  - El-Beshlawy,A
AU  - Belhoul,KM
AU  - Elalfy,M
AU  - Yesilipek,A
AU  - Kilinc,Y
AU  - Lawniczek,T
AU  - Habr,D
AU  - Weisskopf,M
AU  - Zhang,Y
AU  - Aydinok,Y
DO  - 10.1182/blood-2013-04-497842
EP  - 1454
PY  - 2014///
SN  - 0006-4971
SP  - 1447
TI  - A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)
T2  - Blood
UR  - http://dx.doi.org/10.1182/blood-2013-04-497842
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335844600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://ashpublications.org/blood/article/123/10/1447/32349/A-1-year-randomized-controlled-trial-of
VL  - 123
ER  - 

Download